BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) ...
Yahoo Finance

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and ...

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...
Optics

BBO Crystals

Beta-Barium Borate (BBO) is a nonlinear crystal characterised by a broad phase-matchable range from 409.6nm to 3500nm, a wide transmission region from 190nm to 3500nm and a high laser damage threshold ...

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

Detailed price information for Bridgebio Oncology Therapeutics Inc (BBOT-Q) from The Globe and Mail including charting and trades.
TMCnet

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs

BBO-11818 monotherapy demonstrated a confirmed partial response (PR) in pancreatic cancer and anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose ...